Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

  • Technology appraisal guidance
  • TA23
  • Published: 
  • Last updated: 

TA23 Brain cancer - temozolomide: HTA report

This is Health Technology Assessment report on the use of temozolomide for recurrent malignant glioma (brain cancer). It was produced by the Wessex Institute for Health Research and Development, University of Southampton. The HTA report forms part of the evidence submitted to the Appraisal Committee

This page was last updated: 24 December 2010